Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Purpose: The authors investigated whether the addition of whole-brain radiotherapy (WBRT) to stereotactic radiosurgery (SRS) provided any therapeutic benefit according to recursive partitioning analysis (RPA) class.
Methods And Materials: Two hundred forty-five patients with 1 to 10 metastases who underwent SRS between January 2002 and December 2007 were included in the study. Of those, 168 patients were treated with SRS alone and 77 patients received SRS followed by WBRT. Actuarial curves were estimated using the Kaplan-Meier method regarding overall survival (OS), distant brain control (DC), and local brain control (LC) stratified by RPA class. Analyses for known prognostic variables were performed using the Cox proportional hazards model.
Results: Univariate and multivariate analysis revealed that control of the primary tumor, small number of brain metastases, Karnofsky performance scale (KPS) > 70, and initial treatment modalities were significant predictors for survival. For RPA class 1, SRS plus WBRT was associated with a longer survival time compared with SRS alone (854 days vs. 426 days, p = 0.042). The SRS plus WBRT group also showed better LC rate than did the SRS-alone group (p = 0.021), although they did not show a better DC rate (p = 0.079). By contrast, for RPA class 2 or 3, no significant difference in OS, LC, or DC was found between the two groups.
Conclusions: These results suggest that RPA classification should determine whether or not WBRT is added to SRS. WBRT may be recommended to be added to SRS for patients in whom long-term survival is expected on the basis of RPA classification.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ijrobp.2009.08.027 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Single Pontine Relapse Shortly After Hippocampal Avoidance Whole Brain Radiotherapy: A Case Report.
Cancer Rep (Hoboken)
August 2025
Department of Radiation Oncology, American University of Beirut Medical Center, Beirut, Lebanon.
Background: Brain metastasis represents the most prevalent form of brain tumors in adults, with a rising incidence resulting from significant advancements in cancer detection and therapeutic interventions. Current treatment protocols advocate for whole brain radiotherapy (WBRT) for patients who are not candidates for either surgical resection or stereotactic irradiation. However, cognitive decline remains a major side effect of this treatment modality.
View Article and Find Full Text PDFComplete remission of brain metastasis from thymic carcinoma following hypofractionated gamma knife radiosurgery: Case report and a review of literature.
Int J Surg Case Rep
September 2025
Department of Neurosurgery, Gamma Knife Center, Koç University Hospital, Istanbul, Turkey; Department of Neurosurgery, Koç University School of Medicine, Istanbul, Turkey.
Introduction: Thymic carcinoma is a rare, aggressive neoplasm that frequently metastasizes to the lungs, liver, and bones, but rarely to the central nervous system. Less than 50 cases of brain metastases from thymic carcinoma have been documented in the literature, and no consensus exists regarding their optimal management and follow-up.
Case Presentation: Here, we report the case of a 54-year-old male who developed a solitary metastasis in the right temporal region nearly four years after the diagnosis of metastatic thymic carcinoma.
Introduction: This study evaluates hippocampal dosimetry and neurocognitive outcomes in patients undergoing Gamma Knife radiosurgery (GKRS) for benign sellar, parasellar, and suprasellar lesions. While hippocampal protection has been well studied in whole-brain radiotherapy (WBRT), its relevance in stereotactic radiosurgery (SRS) remains underexplored. This study systematically investigates hippocampal radiation dose thresholds and associated neurocognitive outcomes in patients undergoing single-fraction Gamma Knife radiosurgery specifically for benign sellar and parasellar lesions.
View Article and Find Full Text PDFOverview of Preclinical and Clinical Trials of Nanoparticles for the Treatment of Brain Metastases.
Pharmaceutics
July 2025
Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA 94305, USA.
Brain metastases (BM), which most commonly originate from lung, breast, or skin cancers, remain a major clinical challenge, with standard treatments such as stereotactic radiosurgery (SRS), surgical resection, and whole-brain radiation therapy (WBRT). The prognosis for patients with BM remains poor, with a median overall survival (OS) of just 10-16 months. Although recent advances in systemic therapies, including small molecule inhibitors, monoclonal antibodies, chemotherapeutics, and gene therapies, have demonstrated success in other malignancies, their effectiveness in central nervous system (CNS) cancers is significantly limited by poor blood-brain barrier (BBB) permeability and subtherapeutic drug concentrations in the brain.
View Article and Find Full Text PDFIs Anlotinib and Radiotherapy Combination Effective for Non-Small-Cell Lung Cancer with Brain Metastases? A Systematic Scoping Review and Meta-Analysis.
Pharmaceuticals (Basel)
June 2025
Department of Histology, Faculty of Medicine, Assiut University, Assiut 71515, Egypt.
: Non-small-cell lung cancer (NSCLC) frequently metastasizes to the brain, significantly impacting patient prognosis and quality of life. Anlotinib, a novel tyrosine kinase inhibitor, has shown promise in treating NSCLC with brain metastasis. So, we aimed to evaluate the clinical efficacy of anlotinib and various types of radiotherapy combinations used to treat NSCLC patients with brain metastasis regarding overall survival and the treatment of internal and external lesions.
View Article and Find Full Text PDF